|
Researchers at Oregon State University have developed a new analytical method that answers a long-standing question about type 2 diabetes: why do some obese patients develop the condition while others do not.
The research has been published in the journal, "Journal of Experimental Medicine" Type 2 diabetes is a serious metabolic disease that affects roughly one in 10 Americans. Formerly known as adult-onset diabetes, it is a chronic condition affecting the way the body metabolizes glucose, a sugar that's a key source of energy. This type of diabetes is frequently associated with obesity. For some patients, that means their body does not properly respond to insulin - it resists the effects of insulin, the hormone produced by the pancreas that opens the door for sugar to enter cells. In the later disease stages, when the pancreas is exhausted, patients don't produce enough insulin to maintain normal glucose levels. In either case, sugar builds up in the bloodstream and, if left untreated, the effect impairs many major organs, sometimes to disabling or life-threatening degrees. A key risk factor for type 2 diabetes is being overweight, often a result of eating too much fat and sugar in combination with low physical activity. Andrey Morgun and Natalia Shulzhenko of OSU and Giorgio Trinchieri of the National Cancer Institute developed a novel analytical technique, multi-organ network analysis, to explore the mechanisms behind early-stage systemic insulin resistance. The scientists sought to learn which organs, biological pathways and genes are playing roles. In the human body, white adipose tissue is the main type of fat. "Our experiments and analysis predict that a high-fat/high-sugar diet primarily acts in white adipose tissue by driving microbiota-related damage to the energy synthesis process, leading to systemic insulin resistance," said Morgun, associate professor of pharmaceutical sciences at the OSU College of Pharmacy. "Treatments that modify a patient's microbiota in ways that target insulin resistance in adipose tissue macrophage cells could be a new therapeutic strategy for type 2 diabetes." The human gut microbiome features more than 10 trillion microbial cells from about 1,000 different bacterial species. Morgun and Shulzhenko, an associate professor in OSU's Carlson College of Veterinary Medicine, in earlier research developed a computational method, transkingdom network analysis, that predicts specific types of bacteria controlling the expression of mammalian genes connected to specific medical conditions such as diabetes. "Type 2 diabetes is a global pandemic, and the number of diagnoses is expected to keep increasing over the next 10 years," Shulzhenko said. "The so-called 'western diet' - high in saturated fats and refined sugars - is one of the primary factors. But gut bacteria have an important role to play in mediating the effects of diet." In the new study, the scientists relied on both transkingdom network analysis and multi-organ network analysis. They also conducted experiments in mice, looking at the intestine, liver, muscle and white adipose tissue, and examined the molecular signature - which genes were being expressed - of white adipose tissue macrophages in obese human patients. "Diabetes induced by the western diet is characterized by microbiota-dependent mitochondrial damage," Morgun said. "Adipose tissue has a predominant role in systemic insulin resistance, and we characterized the gene expression program and the key master regulator of adipose tissue macrophage that is associated with insulin resistance. We discovered that the Oscillibacter microbe, enriched by a western diet, causes an increase of the insulin-resistant adipose tissue macrophage." The researchers add, however, that Oscillibacter is likely not the only microbial regulator for the expression of the key gene they identified - Mmp12 - and that the Mmp12 pathway, while clearly instrumental, is probably not the only important pathway, depending on which gut microbes are present. "We previously showed that Romboutsia ilealis worsens glucose tolerance by inhibiting insulin levels, which may be relevant to more advanced stages of type 2 diabetes," Shulzhenko said. Zhipeng Li, Manoj Gurung, Jacob W. Pederson, Renee Greer, Stephany Vasquez-Perez and Hyekyoung You of the Carlson College of Veterinary Medicine and Richard Rodrigues, Jyothi Padiadpu, Nolan Newman, and Kaito Hioki from College of Pharmacy also participated in this research, as did scientists from the National Cancer Institute, National Institute of Allergy and Infectious Diseases and Monash University in Australia. (ANI)
|
